Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Other notable gainers include Disc Medicine, which rose 38.9% after positive Phase 3 trial results, and Amaero, which gained 22.8% after its recent IPO. Some stocks like Picard Medical and Republic Power Group also rose without clear catalysts. This deal highlights strong investor interest in biotech acquisitions and promising drug developments.
Silence Therapeutics' recent stock surge is notable. For readers following the health sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: 87 of 150 priced US health stocks rose today. Key movers include SELLAS Life Sciences Group Inc. (SLS) at USD 10.50 with a 5.21% increase, Hinge Health Inc. (HNGE) at USD 103.96 up 4.84%, and Relay Therapeutics Inc. (RLAY) at USD 17.06 gaining 4.79%. Typical hold times on Pluang range from 5 to 10 days for these stocks.
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
Trading in all issues of GoldCoast Resource Corp. (symbol GCR) has resumed at 8:00 AM ET following a temporary halt imposed by the Canadian Investment Regulatory Organization (CIRO). Such halts are used to maintain fair and orderly markets. CIRO over...
Equity Bancshares director Leon Borck increased his stake by purchasing 380 shares at $48.78 each, signaling confidence after the company reported strong Q3 results. The bank posted a net income of $26.8 million and core earnings of $1.40 per diluted...
ICICI Bank reported a 20.1% year-over-year rise in standalone profit after tax to INR 148.43 billion for Q2 FY2027, surpassing earnings estimates with ADR earnings of $0.44 per share versus $0.41 expected. Revenue slightly exceeded forecasts at $3.52...
